What is Shandong Weigao Blood Purification Products Co EBITDA Margin %?
Shandong Weigao Blood Purification Products CoSHSE:603014 +9.99%38 EBITDA Margin % is 15.51% as of Mar. 2026, which is 28% below its 10-year median of 21.51. GuruFocus rates SHSE:603014 with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Shandong Weigao Blood Purification Products Co ranks better than 66.79% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shandong Weigao Blood Purification Products Co EBITDA Margin % Related Terms
Shandong Weigao Blood Purification Products Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Blood Purification Products Co EBITDA Margin % Chart
Shandong Weigao Blood Purification Products Co Annual Data
SHSE:603014 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Shandong Weigao Blood Purification Products Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Weigao Blood Purification Products Co EBITDA Margin % vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a EBITDA Margin % of 15.51% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. This is 28% below median its historical median of 21.51. Over the past decade, Shandong Weigao Blood Purification Products Co's EBITDA Margin % has ranged from 15.42 to 22.39. According to the industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #271 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 33.2%.
Is Shandong Weigao Blood Purification Products Co's EBITDA Margin % too high?
Shandong Weigao Blood Purification Products Co's current EBITDA Margin % of 15.51% is 28% below median its 10-year median of 21.51. Over the past 10 years, this metric has ranged from a low of 15.42 to a high of 22.39. The Medical Devices & Instruments industry median EBITDA Margin % is 7.39. Shandong Weigao Blood Purification Products Co's value of 15.51% is 110% above this industry median. Based on the distribution chart, Shandong Weigao Blood Purification Products Co ranks #271 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shandong Weigao Blood Purification Products Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Blood Purification Products Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #271 out of 816 companies for EBITDA Margin %. This puts Shandong Weigao Blood Purification Products Co in the upper half of its industry. The industry median EBITDA Margin % is 7.39. Shandong Weigao Blood Purification Products Co's value of 15.51% is 110% above this benchmark. Historically, Shandong Weigao Blood Purification Products Co's own EBITDA Margin % has ranged from 15.42 to 22.39 over the past decade. While the company's 10-year median is 21.51 vs. the industry median of 7.39, Shandong Weigao Blood Purification Products Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.39, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Weigao Blood Purification Products Co's current EBITDA Margin % of 15.51% is 110% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Weigao Blood Purification Products Co's current EBITDA Margin % is 15.51%, which is 28% below median its own 10-year median of 21.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Blood Purification Products Co stock overvalued right now?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a current EBITDA Margin % of 15.51%. The current EBITDA Margin % is 15.51%, which is 28% below median its 10-year median of 21.51 and 110% above the Medical Devices & Instruments industry median of 7.39. Shandong Weigao Blood Purification Products Co's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shandong Weigao Blood Purification Products Co (SHSE:603014), the current EBITDA Margin % is 15.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shandong Weigao Blood Purification Products Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603014 has been successfully added to your 
